myasthenia gravis

Comparative Effectiveness and Safety of Emerging Myasthenia Gravis Therapies: Insights From a Bayesian Network Meta-Analysis

By MedXY 07/20/2026

A Bayesian network meta-analysis comparing FcRn inhibitors, C5 complement inhibitors, and CD19+ B-cell depletion therapies reveals comparable efficacy but varied safety profiles in generalized myasthenia gravis treatment, highlighting the need for prospective head-to-head trials.

Neurology news

LRP4 Antibody-Associated Myasthenia Gravis: Distinct Clinical Phenotype and Treatment Challenges in the German MG Registry

By MedXY 07/08/2026

This study reveals that LRP4 antibody-positive myasthenia gravis constitutes a distinct subgroup marked by higher disease severity and treatment escalation compared to other antibody-defined MG types, emphasizing its unique clinical management needs.

Critical Care Neurology news

Navigating the Long Road: Prolonged Ventilator Weaning and High Reintubation Risk in GBS and Myasthenia Gravis

By MedXY 12/26/2025

A large-scale multicenter study reveals that while patients with Guillain-Barré syndrome face significantly longer weaning times and higher tracheostomy rates than those with myasthenia gravis, both groups experience alarmingly high reintubation rates despite an overall low mortality rate.

Neurology news

FDA Approves Inebilizumab (Uplizna) for Antibody-Positive Generalized Myasthenia Gravis: Interpreting the MINT Trial and Clinical Implications

By MedXY 12/15/2025

The FDA has approved inebilizumab-cdon (Uplizna) for adults with AChR- or MuSK-antibody positive generalized myasthenia gravis based on the phase 3 MINT trial showing a 1.9-point MG‑ADL improvement at 26 weeks versus placebo and sustained benefit in AChR+ patients through 52 weeks.

Neurology news

Efgartigimod Shows Benefit in AChR‑Antibody–Negative Generalized Myasthenia Gravis — New Data from ADAPT SERON

By MedXY 11/05/2025

Phase 3 ADAPT SERON data show efgartigimod improves MG‑ADL scores in AChR‑Ab–negative gMG, with pronounced benefit in MuSK‑positive patients; results for triple‑seronegative disease were inconclusive. Safety profile was consistent with prior experience.

Clinical Updates Diabetes & Endocrinology news Specialties

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY 08/01/2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.